@article{5094a53d1a51451b972b1ce7be46c208,
title = "JPOS/JASCC clinical guidelines for delirium in adult cancer patients: A summary of recommendation statements",
abstract = "Background: The Japanese Psycho-Oncology Society and Japanese Association of Supportive Care in Cancer recently launched the clinical practice guidelines for delirium in adult cancer patients. The aim of the guidelines was to provide evidence-based recommendations for the clinical assessment and management of delirium in cancer patients. This article reports the process of developing the guideline and summarizes the recommendations made. Methods: The guidelines were developed in accordance with the Medical Information Network Distribution Service creation procedures. The guideline development group, consisting of multidisciplinary members, formulated nine clinical questions. A systematic literature search was conducted to identify relevant articles published prior to through 31 May 2016. Each article was reviewed by two independent reviewers. The level of evidence and the strength of the recommendations were graded using the grading system developed by the Medical Information Network Distribution Service, following the concept of The Grading of Recommendations Assessment, Development and Evaluation system. The modified Delphi method was used to validate the recommendation statements. Results: This article provides a summary of the recommendations with rationales for each, as well as a short summary. Conclusions: These guidelines will support the clinical assessment and management of delirium in cancer patients. However, additional clinical studies are warranted to further improve the management of delirium.",
keywords = "Cancer, Delirium, Guideline, Palliative care, Psycho-oncology",
author = "Yoshinobu Matsuda and Hitoshi Tanimukai and Shinichiro Inoue and Shuji Inada and Koji Sugano and Hideaki Hasuo and Masafumi Yoshimura and Saho Wada and Chikako Dotani and Hiroyoshi Adachi and Yoshiaki Okamoto and Mari Takeuchi and Daisuke Fujisawa and Jun Kako and Chiyuki Sasaki and Yasuhiro Kishi and Nobuya Akizuki and Masatoshi Inagaki and Yosuke Uchitomi and Eisuke Matsushima and Toru Okuyama",
note = "Funding Information: This work was funded by the Japan Psycho-Oncology Society and was supported in part by Health, Labour and Welfare Sciences Research Grants: Research for Promotion of Cancer Control Programmes (19EA1009). Funding Information: Dr. Adachi received a grant from Eisai Co., Ltd. outside the submitted work as well as lecture fees from MSD K.K. and Eisai Co., Ltd. outside the submitted work. Dr. Kishi reports receiving honoraria from Shionogi & Co., Ltd., Merck Sharp & Dohme, Otsuka, Pfizer, Mochida, Eli Lilly, Daiichi-Sankyo Co., Ltd., Eisai Co., Ltd., Dainihon-Sumitomo, Tanabe-Mitsubishi and Tsumura as well as serving as a consultant for Meiji and Merck Sharp & Dohme. Dr. Inagaki has received lecture fees from Meiji, Mochida, Takeda, Novartis, Yoshitomi, Pfizer Japan Inc., Eisai Co., Ltd, Otsuka, MSD and Sumitomo Dainippon and personal fees from Technomics. Dr. Inagaki has also received research funds from Novartis. Dr. Okuyama reports receiving grants from the Ministry of Health, Labour and Welfare, Japan, and the Japanese Society for the Promotion of Science. During the conduct of the study, personal fees (outside the submitted work) were received from the following companies: Chugai Pharmaceutical Co., Ltd., MSD K.K., Daiichi-Sankyo Co., Ltd, Shionogi & Co., Ltd, Pfizer Japan Inc. and Terumo Corporation. Publisher Copyright: {\textcopyright} The Author(s) 2020.",
year = "2021",
doi = "10.1093/JJCO/HYAA003",
language = "English",
volume = "50",
pages = "586--593",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",
}